Bausch Health Companies Inc. (BHC)
NYSE
Market Cap
$2.8B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
440 of 951
Rank in Industry
23 of 57
Largest Insider Buys in Sector
BHC Stock Price History Chart
BHC Stock Performance
About Bausch Health Companies Inc.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Insider Activity of Bausch Health Companies Inc.
Over the last 12 months, insiders at Bausch Health Companies Inc. have bought $0 and sold $148,569 worth of Bausch Health Companies Inc. stock.
On average, over the past 5 years, insiders at Bausch Health Companies Inc. have bought $102.79M and sold $10.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 60,000 shares for transaction amount of $1.45M was made by Miller Steven D (director) on 2021‑11‑30.
List of Insider Buy and Sell Transactions, Bausch Health Companies Inc.
| 2024-12-02 | Sale | EVP, General Counsel | 440 0.0001% | $8.35 | $3,674 | -0.58% | ||
| 2024-09-06 | Sale | EVP, General Counsel | 13,370 0.0036% | $6.21 | $83,028 | +30.43% | ||
| 2024-03-04 | Sale | EVP, General Counsel | 6,313 0.0018% | $9.80 | $61,867 | -17.85% | ||
| 2023-12-05 | Sale | EVP, General Counsel | 220 <0.0001% | $7.38 | $1,624 | +13.07% | ||
| 2023-11-06 | Sale | EVP, General Counsel | 43 <0.0001% | $7.61 | $327 | +4.86% | ||
| 2023-09-06 | Sale | EVP, General Counsel | 6,685 0.0018% | $8.28 | $55,352 | -8.67% | ||
| 2023-03-06 | Sale | EVP, General Counsel | 495 0.0001% | $9.17 | $4,539 | -10.20% | ||
| 2023-03-03 | Sale | EVP, General Counsel | 780 0.0002% | $9.34 | $7,285 | -14.30% | ||
| 2023-02-28 | Sale | EVP, General Counsel | 292 <0.0001% | $9.32 | $2,721 | -15.31% | ||
| 2022-04-14 | Sale | U.S. President-Pharma Business | 1,595 0.0004% | $22.19 | $35,393 | -65.94% | ||
| 2022-03-15 | Sale | U.S. President-Pharma Business | 4,846 0.0014% | $22.20 | $107,581 | -65.00% | ||
| 2022-03-08 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 3,889 0.0011% | $21.76 | $84,625 | -64.35% | ||
| 2022-03-02 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 11,077 0.003% | $23.37 | $258,869 | -68.14% | ||
| 2022-03-02 | Sale | U.S. President-Pharma Business | 1,595 0.0004% | $23.37 | $37,275 | -68.14% | ||
| 2022-03-01 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 6,338 0.0018% | $23.82 | $150,971 | -67.14% | ||
| 2022-02-15 | Sale | U.S. President-Pharma Business | 3,251 0.0009% | $25.02 | $81,340 | -69.84% | ||
| 2022-01-18 | Sale | U.S. President-Pharma Business | 3,251 0.0009% | $26.63 | $86,574 | -70.45% | ||
| 2021-11-30 | director | 60,000 0.017% | $24.23 | $1.45M | -60.82% | |||
| 2021-08-05 | director | 2,800 0.0008% | $25.94 | $72,632 | -6.04% | |||
| 2021-08-04 | director | 20,000 0.0056% | $25.01 | $500,246 | -2.62% |
Insider Historical Profitability
11.48%
| Carson Seana | EVP, General Counsel | 433066 0.1177% | $7.62 | 0 | 9 | |
| Paulson John | 25839035 7.0252% | $7.62 | 5 | 2 | +31.4% | |
| ValueAct Holdings, L.P. | director | 17931594 4.8753% | $7.62 | 19 | 3 | +19.98% |
| Pearson J. Michael | Chief Executive Officer | 1514664 0.4118% | $7.62 | 2 | 1 | +21.28% |
| Morfit G Mason | See Remarks | 1352941 0.3678% | $7.62 | 1 | 0 | +30.3% |
| UBBEN JEFFREY W | director | 1059793 0.2881% | $7.62 | 3 | 1 | +44.4% |
| PAPA JOSEPH C | CHAIRMAN & CEO | 839601 0.2283% | $7.62 | 5 | 0 | +0.47% |
| Rosiello Robert L. | EVP, Chief Financial Officer | 441675 0.1201% | $7.62 | 3 | 0 | <0.0001% |
| DE SCHUTTER RICHARD U | director | 317109 0.0862% | $7.62 | 10 | 0 | +15.65% |
| DE SILVA RAJIV | President and COO | 265217 0.0721% | $7.62 | 1 | 3 | +16.48% |
| Humphries William D. | President, Ortho-Dermatologics | 235035 0.0639% | $7.62 | 1 | 5 | <0.0001% |
| INGRAM ROBERT ALEXANDER | director | 217724 0.0592% | $7.62 | 0 | 1 | |
| Herendeen Paul | EVP and CFO | 216866 0.059% | $7.62 | 3 | 0 | +27.32% |
| Schiller Howard Bradley | Chairman and CEO | 182900 0.0497% | $7.62 | 8 | 0 | +11.49% |
| ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | 166758 0.0453% | $7.62 | 1 | 5 | <0.0001% |
| Provencio Norma Ann | director | 137495 0.0374% | $7.62 | 6 | 8 | +18.22% |
| Loberg Philip Walden Jr | EVP, Interim CFO | 137565 0.0374% | $7.62 | 1 | 0 | <0.0001% |
| APPIO THOMAS | Pres&Co-Head Bausch&Lomb/Int'l | 128922 0.0351% | $7.62 | 1 | 0 | +3.24% |
| Eldessouky Sam | EVP & Chief Financial Officer | 116857 0.0318% | $7.62 | 0 | 1 | |
| WECHSLER AMY B | director | 98325 0.0267% | $7.62 | 0 | 1 | |
| Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | 93139 0.0253% | $7.62 | 0 | 3 | |
| Spurr Robert | U.S. President-Pharma Business | 90506 0.0246% | $7.62 | 0 | 5 | |
| Masterson Richard Kevin | Pres. & COO, Valeant Intl. BB | 89524 0.0243% | $7.62 | 0 | 1 | |
| Ross Thomas W. Sr. | director | 79242 0.0215% | $7.62 | 3 | 0 | <0.0001% |
| Wells William McDowall | director | 75000 0.0204% | $7.62 | 0 | 3 | |
| Durham Mark Andrew | SVP Human Resources | 61595 0.0167% | $7.62 | 0 | 2 | |
| Miller Steven D | director | 60780 0.0165% | $7.62 | 1 | 0 | <0.0001% |
| PAUL LAURENCE E | director | 60459 0.0164% | $7.62 | 5 | 0 | +19.25% |
| Hassan Fred | director | 53969 0.0147% | $7.62 | 1 | 0 | +22.43% |
| Kornwasser Laizer | EVP, Company Group Chairman | 53582 0.0146% | $7.62 | 6 | 0 | +16.39% |
| Chai-Onn Robert Roswell | EVP, CLO, General Counsel | 43187 0.0117% | $7.62 | 2 | 6 | +7.18% |
| VON ESCHENBACH ANDREW C. | director | 38647 0.0105% | $7.62 | 2 | 0 | <0.0001% |
| Stolz Brian M. | EVP, Administration & CHCO | 32156 0.0087% | $7.62 | 7 | 0 | +19.31% |
| Squires Douglas John Paul | director | 29688 0.0081% | $7.62 | 0 | 1 | |
| STEVENSON KATHARINE BERGHUIS | director | 23098 0.0063% | $7.62 | 4 | 0 | +35.79% |
| Segal Lloyd Mitchell | director | 21174 0.0058% | $7.62 | 5 | 0 | +36.29% |
| KARABELAS ARGERIS N | director | 20726 0.0056% | $7.62 | 1 | 0 | <0.0001% |
| McKenna Mark C. | President, Salix | 20756 0.0056% | $7.62 | 0 | 1 | |
| Farmer Ronald Harold | director | 15532 0.0042% | $7.62 | 15 | 0 | <0.0001% |
| Mirovsky Pavel | EVP, Pres. & GM Valeant EMENA | 13675 0.0037% | $7.62 | 0 | 3 | |
| Whitaker Anne Clem | director | 7500 0.002% | $7.62 | 1 | 0 | <0.0001% |
| Chouinard Michel | COO, Biovail Labs. Intl SRL | 2470 0.0007% | $7.62 | 0 | 4 | |
| Pershing Square Capital Management, L.P. | See footnote (3) | 0 0% | $7.62 | 0 | 2 | |
| Fibiger Hans Christian | Chief Scientific Officer | 0 0% | $7.62 | 0 | 1 | |
| Mayer Christine | SVP, BTA Pharmaceuticals, Inc. | 0 0% | $7.62 | 0 | 1 | |
| Hall Susan | Global Head of R&D | 0 0% | $7.62 | 0 | 1 |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| ICAHN CARL C | $368.39M | 9.62 | 34.72M | 0% | +$0 | 3.29 | |
| GoldenTree Asset Management | $293.31M | 7.66 | 27.64M | 0% | +$0 | 25.67 | |
| Paulson & Co. | $280.52M | 7.32 | 26.44M | 0% | +$0 | 19.38 | |
| Franklin Templeton Investments | $168.18M | 4.39 | 15.85M | +0.32% | +$528,788.17 | 0.05 | |
| National Bank Of Canada Fi | $107.75M | 4.34 | 15.66M | +0.07% | +$80,874.83 | 0.18 | |
| Nomura Holdings | $163.08M | 4.26 | 15.37M | +15.6% | +$22.01M | 1.42 | |
| Healthcare Of Ontario Pension Plan Trust Fund | $137.93M | 3.6 | 13M | 0% | +$0 | 0.42 | |
| Hudson Bay Capital Management LP | $124.67M | 3.26 | 11.75M | +2.17% | +$2.65M | 0.84 | |
| Royal Bank of Canada | $124.31M | 3.25 | 11.72M | -0.23% | -$291,912.37 | 0.03 | |
| The Vanguard Group | $124.29M | 3.25 | 11.71M | +0.99% | +$1.22M | <0.01 | |
| ING Group | $79.58M | 2.08 | 7.5M | 0% | +$0 | 0.55 | |
| Mizuho Markets Americas Llc | $74.27M | 1.94 | 7M | 0% | +$0 | 1.69 | |
| Laurion Capital Management LP | $64.46M | 1.68 | 6.08M | -29.65% | -$27.17M | 0.46 | |
| Mfn Partners Management Lp | $63.66M | 1.66 | 6M | 0% | +$0 | 1.94 | |
| Kohlberg Kravis Roberts | $55.54M | 1.45 | 5.24M | 0% | +$0 | 1.77 | |
| Arrowstreet Capital, Limited Partnership | $44.11M | 1.15 | 4.16M | +514.43% | +$36.93M | 0.04 | |
| Citadel Advisors LLC | $40.87M | 1.07 | 3.85M | -43.68% | -$31.7M | 0.02 | |
| Natixis | $38.71M | 1.01 | 3.65M | +14.27% | +$4.83M | 0.22 | |
| Hillsdale Investment Management Inc. | $36.13M | 0.94 | 3.41M | +1,050.81% | +$32.99M | 2.89 | |
| Dimensional Fund Advisors | $29.96M | 0.78 | 2.82M | -1.51% | -$459,519.09 | 0.01 | |
| SG Americas Securities, LLC | $23.35M | 0.61 | 2.2M | +3,080.92% | +$22.61M | 0.12 | |
| Morgan Stanley | $22.22M | 0.58 | 2.09M | -4.47% | -$1.04M | <0.01 | |
| Goldman Sachs | $21.08M | 0.55 | 1.99M | +35.56% | +$5.53M | <0.01 | |
| Man Group Plc | $18.01M | 0.47 | 1.7M | -2.97% | -$551,836.70 | 0.04 | |
| Hein Park Capital Management LP | $17.54M | 0.46 | 1.65M | +56.95% | +$6.37M | 14.27 | |
| Whitebox Advisors | $16.32M | 0.43 | 1.54M | -18.66% | -$3.74M | 1.86 | |
| Bank of Montreal | $15.79M | 0.42 | 1.5M | -50.29% | -$15.98M | 0.01 | |
| Deutsche Bank | $15.43M | 0.4 | 1.45M | +118.61% | +$8.37M | 0.01 | |
| D. E. Shaw & Co. | $14.13M | 0.37 | 1.33M | +66.76% | +$5.66M | 0.01 | |
| Oaktree Capital Management | $13.79M | 0.36 | 1.3M | 0% | +$0 | 0.37 | |
| GAMCO Investors | $13.28M | 0.35 | 1.25M | -1.31% | -$176,465.52 | 0.14 | |
| Millennium Management LLC | $12.21M | 0.32 | 1.15M | +72.57% | +$5.13M | 0.01 | |
| Canada Pension Plan Investment Board | $12.13M | 0.32 | 1.14M | 0% | +$0 | 0.01 | |
| Td Asset Management Inc | $12.14M | 0.32 | 1.14M | -1.02% | -$125,637.39 | 0.01 | |
| Mackenzie Financial Corp | $11.97M | 0.31 | 1.13M | -27.75% | -$4.6M | 0.02 | |
| PRIVATE MANAGEMENT GROUP, INC. | $11.1M | 0.29 | 1.05M | -0.42% | -$46,959.86 | 0.43 | |
| Nine Masts Capital Ltd | $9.28M | 0.24 | 874,500 | New | +$9.28M | 6.65 | |
| Bank of America | $8.36M | 0.22 | 788,085 | -24.21% | -$2.67M | <0.01 | |
| Chou Associates Management Inc | $7.76M | 0.2 | 715,000 | 0% | +$0 | 9.04 | |
| Rokos Capital Management | $7.29M | 0.19 | 687,318 | -54.18% | -$8.61M | 0.19 | |
| Soleus Capital Management, L.P. | $7.11M | 0.19 | 670,000 | New | +$7.11M | 0.03 | |
| Public Sector Pension Investment Board | $6.39M | 0.17 | 602,663 | 0% | +$0 | 0.05 | |
| Credit Suisse | $5.96M | 0.16 | 562,172 | -17.61% | -$1.27M | 0.01 | |
| CIBC World Markets | $5.77M | 0.15 | 544,529 | +163.86% | +$3.58M | 0.02 | |
| Swiss National Bank | $5.73M | 0.15 | 541,460 | 0% | +$0 | <0.01 | |
| Cubist Systematic Strategies | $5.72M | 0.15 | 539,226 | +829.35% | +$5.11M | 0.05 | |
| Barclays | $5.55M | 0.15 | 523,245 | -37.62% | -$3.35M | <0.01 | |
| Geode Capital Management | $5.52M | 0.12 | 428,397 | -0.19% | -$10,699.32 | <0.0001 | |
| Woodline Partners LP | $4.34M | 0.11 | 409,333 | New | +$4.34M | 0.04 | |
| LOMBARD ODIER ASSET MANAGEMENT (USA) CORP | $4.24M | 0.11 | 400,000 | 0% | +$0 | 0.63 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.